Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma

PURPOSE: Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin for which effective therapies are lacking. We conducted a phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib in patients with R/M ACC. PATI...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Tchekmedyian, Vatche, Sherman, Eric J., Dunn, Lara, Tran, Crystal, Baxi, Shrujal, Katabi, Nora, Antonescu, Cristina R., Ostrovnaya, Irina, Haque, Sofia S., Pfister, David G., Ho, Alan L.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2019
Sujets:
RAPID COMMUNICATIONS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6599407/
https://ncbi.nlm.nih.gov/pubmed/30939095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01859
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires